Developments in the...

Developments in the Management of BCG-Unresponsive NMIBC  


New Member Admin
Joined: 4 years ago
Posts: 400
24/09/2018 3:29 pm  

A good overview on treatment options for non-muscle invasive bladder cancer (NMIBC)

One other drug that seems to be very effective and was not discussed in the above reference is Vicinium (VB4-845) made by Sesen Bio Inc. currently being evaluated in the Phase 3 VISTA trial. In a Phase 2 clinical trial, Vicinium demonstrated a complete response rate of 40 percent at three months, with no drug-related serious adverse events observed in the trial. In addition to its Phase 3 development for NMIBC, Vicinium is being evaluated in a Phase 1 trial in combination with durvalumab, AstraZeneca’s PD-L1 checkpoint inhibitor, in patients with NMIBC.

This topic was modified 12 months ago by Daniel